[go: up one dir, main page]

MX2020002014A - Peptido inmunogenico contra estreptococo del grupo a. - Google Patents

Peptido inmunogenico contra estreptococo del grupo a.

Info

Publication number
MX2020002014A
MX2020002014A MX2020002014A MX2020002014A MX2020002014A MX 2020002014 A MX2020002014 A MX 2020002014A MX 2020002014 A MX2020002014 A MX 2020002014A MX 2020002014 A MX2020002014 A MX 2020002014A MX 2020002014 A MX2020002014 A MX 2020002014A
Authority
MX
Mexico
Prior art keywords
peptide
streptococcus
immunogenic peptide
peptide against
modified
Prior art date
Application number
MX2020002014A
Other languages
English (en)
Inventor
Manisha Pandey
Michael F Good
Michael Raymond Batzloff
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Griffith filed Critical Univ Griffith
Publication of MX2020002014A publication Critical patent/MX2020002014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido p145 modificado que tiene inmunogenicidad de la mucosa aumentada para el uso en inducir una respuesta inmune de la mucosa a las bacterias estreptocócicas del grupo A en un mamífero tal como un humano. La administración intramuscular del péptido p145 modificado puede ser particularmente eficaz. Un péptido S2 o variante se puede co-administrar con el péptido p145 modificado para. aumentar la respuesta inmune.
MX2020002014A 2017-08-23 2018-08-22 Peptido inmunogenico contra estreptococo del grupo a. MX2020002014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2019439 2017-08-23
PCT/AU2018/050893 WO2019036761A1 (en) 2017-08-23 2018-08-22 IMMUNOGENIC PEPTIDE DIRECTED AGAINST GROUP A STREPTOCOCCUS

Publications (1)

Publication Number Publication Date
MX2020002014A true MX2020002014A (es) 2020-10-14

Family

ID=60515757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002014A MX2020002014A (es) 2017-08-23 2018-08-22 Peptido inmunogenico contra estreptococo del grupo a.

Country Status (11)

Country Link
US (2) US11732033B2 (es)
EP (1) EP3672628A4 (es)
JP (1) JP7410018B2 (es)
KR (1) KR102893870B1 (es)
CN (1) CN111344007A (es)
AU (1) AU2018322485B2 (es)
BR (1) BR112020003734A2 (es)
CA (1) CA3073580A1 (es)
MX (1) MX2020002014A (es)
SG (1) SG11202001557PA (es)
WO (1) WO2019036761A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131575B1 (en) * 2014-04-15 2024-05-08 Griffith University Group a streptococcus vaccine
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides
JP6059220B2 (ja) * 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
EP3131575B1 (en) * 2014-04-15 2024-05-08 Griffith University Group a streptococcus vaccine
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗

Also Published As

Publication number Publication date
KR20200046059A (ko) 2020-05-06
AU2018322485A1 (en) 2020-03-12
SG11202001557PA (en) 2020-03-30
EP3672628A4 (en) 2021-06-30
JP7410018B2 (ja) 2024-01-09
US20230382981A1 (en) 2023-11-30
AU2018322485B2 (en) 2024-02-01
RU2020111297A (ru) 2021-09-23
US11732033B2 (en) 2023-08-22
JP2021505525A (ja) 2021-02-18
US12383630B2 (en) 2025-08-12
BR112020003734A2 (pt) 2020-09-01
US20210024619A1 (en) 2021-01-28
EP3672628A1 (en) 2020-07-01
CN111344007A (zh) 2020-06-26
RU2020111297A3 (es) 2021-12-23
KR102893870B1 (ko) 2025-12-02
WO2019036761A1 (en) 2019-02-28
CA3073580A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AR105470A1 (es) Métodos para inducir una respuesta inmune
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CO2018001534A2 (es) Una composicion de vacuna arboviral
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
ES2721930T3 (es) Composición inmunogénica
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CO2020000328A2 (es) Formulaciones a largo plazo
CL2016002732A1 (es) Suplementación microbioma neonatal
MX2015010555A (es) Composiciones y metodos para mejorar las respuestas inmunes ante una infeccion por eimeria o una infeccion limitante por eimeria.
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
AR092897A1 (es) Composiciones inmunogenicas
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX363464B (es) Vacunas contra influenza h5.
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
MX2016013277A (es) Vacuna para estreptococo de grupo a.
MX2020002014A (es) Peptido inmunogenico contra estreptococo del grupo a.
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа